Jump to ContentJump to Main Navigation
Schizophrenia – Evolution and Synthesis - MIT Press Scholarship Online
Users without a subscription are not able to see the full content.

Schizophrenia: Evolution and Synthesis

Steven M. Silverstein, Bita Moghaddam, and Til Wykes

Abstract

Despite major advances in methodology and thousands of published studies every year, treatment outcomes in schizophrenia have not improved over the last fifty years. Moreover, we still lack strategies for prevention and we do not yet understand how the interaction of genetic, developmental, and environmental factors contribute to the disorder. In this volume of the Strungmann Forum Reports Series leading researchers consider conceptual and technical obstacles to progress in understanding schizophrenia and suggest novel strategies for advancing research and treatment.

Keywords: Schizophrenia, Heterogeneity, Risk, Prevention, Modelling, Treatment, Outcome, Cognition, Rehabilitation

Bibliographic Information

Print publication date: 2013 Print ISBN-13: 9780262019620
Published to MIT Press Scholarship Online: May 2014 DOI:10.7551/mitpress/9780262019620.001.0001

Authors

Affiliations are at time of print publication.

Steven M. Silverstein, editor

Bita Moghaddam, editor

Til Wykes, editor

Show Summary Details

subscribe or login to access all content.

Contents

View:

Front Matter

Title Pages

Strüngmann Forum Reports

The Ernst Strüngmann Forum

List of Contributors

1 Schizophrenia

Steven M. Silverstein, Bita Moghaddam, and Til Wykes

Heterogeneity

2 What Kind of a Thing Is Schizophrenia?

Angus W. MacDonald

3 How the Diagnosis of Schizophrenia Impeded the Advance of Knowledge (and What to Do About It)

William T. Carpenter

4 What Dimensions of Heterogeneity Are Relevant for Treatment Outcome?

Leanne M. Williams, and Chloe Gott

5 Which Aspects of Heterogeneity Are Useful to Translational Success?

Aiden Corvin, Robert W. Buchanan, William T. Carpenter, James L. Kennedy, Matcheri S. Keshavan, Angus W. MacDonald, Louis Sass, and Michéle Wessa

Risk and Resilience

6 How Should Resilience Factors Be Incorporated in Treatment Development?

Peter B. Jones

7 Insights into New Treatments for Early Psychosis from Genetic, Neurodevelopment, and Cognitive Neuroscience Research

Kristin S. Cadenhead, and Camilo de la Fuente-Sandoval

8 From Epidemiology to Mechanisms of Illness

John McGrath, and Andreas Meyer-Lindenberg

9 How Can Risk and Resilience Factors Be Leveraged to Optimize Discovery Pathways?

Craig Morgan, Michael O’Donovan, Robert A. Bittner, Kristin S. Cadenhead, Peter B. Jones, John McGrath, Steven M. Silverstein, Heike Tost, Peter Uhlhaas, and Aristotle Voineskos

Models

10 Human Cell Models for Schizophrenia

Ashley M. Wilson, and Akira Sawa

11 How Can Animal Models Be Better Utilized?

Patricio O’Donnell

12 How Can Computational Models Be Better Utilized for Understanding and Treating Schizophrenia?

Daniel Durstewitz, and Jeremy K. Seamans

13 How Can Models Be Better Utilized to Enhance Outcome?

Kevin J. Mitchell, Patricio O’Donnell, Daniel Durstewitz, André A. Fenton, Jay A. Gingrich, Joshua A. Gordon, Wolfgang Kelsch, William A. Phillips, and Akira Sawa

Development and Treatment

14 Why Kraepelin Was Right

René S. Kahn

15 What Will the Next Generation of Psychosocial Treatments Look Like?

Kim T. Mueser

16 Creative Solutions to Overcoming Barriers in Treatment Utilization

Wulf Rössler

17 What Is Necessary to Enhance Development and Utilization of Treatment?

Vera A. Morgan, Richard Keefe, René S. Kahn, Anil K. Malhotra, Andreas Meyer-Lindenberg, Kim T. Mueser, Karoly Nikolich, Wulf Rössler, William Spaulding, Sharmili Sritharan, and Til Wykes

End Matter

Bibliography

Subject Index